Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma
Articolo
Data di Pubblicazione:
2017
Citazione:
Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma / R. Finotello, D. Stefanello, E. Zini, L. Marconato. - In: VETERINARY AND COMPARATIVE ONCOLOGY. - ISSN 1476-5810. - 15:1(2017 Mar 01), pp. 25-35. [10.1111/vco.12139]
Abstract:
Canine hemangiosarcoma (HSA) is a neoplasm of vascular endothelial origin that has an aggressive biological behaviour, with less than 10% of dogs alive at 12-months postdiagnosis. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Twenty-seven dogs were enrolled; following staging work-up, 18 were treated with AC and 9 with ADTIC. Median TTM and survival time were longer for dogs treated with ADTIC compared with those receiving AC (>550 versus 112days, P=0.021 and >550 versus 142days, P=0.011, respectively). Both protocols were well tolerated, without need for dose reduction or increased interval between treatments. A protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with HSA and prolongs TTM and survival time.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Cyclophosphamide; Dacarbazine; Dog; Doxorubicin; Hemangiosarcoma; Veterinary (all)
Elenco autori:
R. Finotello, D. Stefanello, E. Zini, L. Marconato
Link alla scheda completa: